Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
Russell Lewis, Jan Philipp Bewersdorf, Amer M Zeidan Department of Medicine, Section of Hematology, Yale University, New Haven, CT, USACorrespondence: Amer M ZeidanDepartment of Medicine, Section of Hematology, Smilow Cancer Center at Yale New Haven Hospital, 333 Cedar Street, PO Box 208028, New Hav...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-01-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-management-of-anemia-in-patients-with-myelodysplastic-syndrom-peer-reviewed-article-CMAR |
| _version_ | 1818452109137281024 |
|---|---|
| author | Lewis R Bewersdorf JP Zeidan AM |
| author_facet | Lewis R Bewersdorf JP Zeidan AM |
| author_sort | Lewis R |
| collection | DOAJ |
| description | Russell Lewis, Jan Philipp Bewersdorf, Amer M Zeidan Department of Medicine, Section of Hematology, Yale University, New Haven, CT, USACorrespondence: Amer M ZeidanDepartment of Medicine, Section of Hematology, Smilow Cancer Center at Yale New Haven Hospital, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8028, USAEmail amer.zeidan@yale.eduAbstract: For the majority of patients with lower-risk myelodysplastic syndrome (LR-MDS), one of the primary clinical goals is to alleviate the symptoms associated with the resultant cytopenias and to minimize the transfusion burden. While supportive red blood cell (RBC) transfusions and erythropoiesis-stimulating agents (ESAs) may lead to clinical improvement, frequent transfusions are often complicated by iron overload and decreased quality of life; furthermore, most patients either do not respond to ESAs or will eventually develop resistance. As such, there is a great need for further therapeutic options in the management of anemia related to MDS. Several additional therapeutics are now available in select patients with LR-MDS and symptomatic anemia including luspatercept, lenalidomide, and immunosuppressive therapy. Furthermore, several novel agents are currently in development to address this area of clinical need such as imetelstat and roxadustat. In this article, we review the currently available therapeutic options for symptomatic anemia in LR-MDS as well as review the therapeutic agents in development.Keywords: myelodysplastic syndrome, erythropoiesis-stimulating agents, novel agents, clinical trials |
| first_indexed | 2024-12-14T21:17:52Z |
| format | Article |
| id | doaj.art-0a985db87df14bdfab4711b5dc5c0368 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-14T21:17:52Z |
| publishDate | 2021-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-0a985db87df14bdfab4711b5dc5c03682022-12-21T22:47:01ZengDove Medical PressCancer Management and Research1179-13222021-01-01Volume 1364565761468Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic OptionsLewis RBewersdorf JPZeidan AMRussell Lewis, Jan Philipp Bewersdorf, Amer M Zeidan Department of Medicine, Section of Hematology, Yale University, New Haven, CT, USACorrespondence: Amer M ZeidanDepartment of Medicine, Section of Hematology, Smilow Cancer Center at Yale New Haven Hospital, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8028, USAEmail amer.zeidan@yale.eduAbstract: For the majority of patients with lower-risk myelodysplastic syndrome (LR-MDS), one of the primary clinical goals is to alleviate the symptoms associated with the resultant cytopenias and to minimize the transfusion burden. While supportive red blood cell (RBC) transfusions and erythropoiesis-stimulating agents (ESAs) may lead to clinical improvement, frequent transfusions are often complicated by iron overload and decreased quality of life; furthermore, most patients either do not respond to ESAs or will eventually develop resistance. As such, there is a great need for further therapeutic options in the management of anemia related to MDS. Several additional therapeutics are now available in select patients with LR-MDS and symptomatic anemia including luspatercept, lenalidomide, and immunosuppressive therapy. Furthermore, several novel agents are currently in development to address this area of clinical need such as imetelstat and roxadustat. In this article, we review the currently available therapeutic options for symptomatic anemia in LR-MDS as well as review the therapeutic agents in development.Keywords: myelodysplastic syndrome, erythropoiesis-stimulating agents, novel agents, clinical trialshttps://www.dovepress.com/clinical-management-of-anemia-in-patients-with-myelodysplastic-syndrom-peer-reviewed-article-CMARmyelodysplastic syndromeerythropoiesis stimulating agentsnovel agentsclinical trials |
| spellingShingle | Lewis R Bewersdorf JP Zeidan AM Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options Cancer Management and Research myelodysplastic syndrome erythropoiesis stimulating agents novel agents clinical trials |
| title | Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
| title_full | Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
| title_fullStr | Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
| title_full_unstemmed | Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
| title_short | Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
| title_sort | clinical management of anemia in patients with myelodysplastic syndromes an update on emerging therapeutic options |
| topic | myelodysplastic syndrome erythropoiesis stimulating agents novel agents clinical trials |
| url | https://www.dovepress.com/clinical-management-of-anemia-in-patients-with-myelodysplastic-syndrom-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT lewisr clinicalmanagementofanemiainpatientswithmyelodysplasticsyndromesanupdateonemergingtherapeuticoptions AT bewersdorfjp clinicalmanagementofanemiainpatientswithmyelodysplasticsyndromesanupdateonemergingtherapeuticoptions AT zeidanam clinicalmanagementofanemiainpatientswithmyelodysplasticsyndromesanupdateonemergingtherapeuticoptions |